Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study by Tisdale, James E. et al.
Influence of Oral Progesterone Administration on Drug-Induced 
QT Interval Lengthening: A Randomized, Double-Blind, Placebo-
Controlled Crossover Study
James E. Tisdale, PharmD*,†, Heather A. Jaynes, MSN*, Brian R. Overholser, PharmD*,†, 
Kevin M. Sowinski, PharmD*,†, David A. Flockhart, MD, PhD†, and Richard J. Kovacs, MD‡
*Department of Pharmacy Practice, College of Pharmacy, Purdue University, Indianapolis, Indiana
†Division of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana 
University, Indianapolis, Indiana
‡Krannert Institute of Cardiology, Department of Medicine, School of Medicine, Indiana University, 
Indianapolis, Indiana
Abstract
Objectives—We tested the hypothesis that oral progesterone administration attenuates drug-
induced QT interval lengthening.
Background—Evidence from preclinical and human investigations suggests that higher serum 
progesterone concentrations may be protective against drug-induced QT interval lengthening.
Methods—In this prospective, double-blind, crossover study, 19 healthy female volunteers 
(21-40 years) were randomized to receive progesterone 400 mg or matching placebo orally once 
daily for 7 days timed to the menses phase of the menstrual cycle (between-phase washout period 
= 49 days). On day 7, ibutilide 0.003 mg/kg was infused over 10 minutes, after which QT intervals 
were recorded and blood samples collected for 12 hours. Prior to the treatment phases, subjects 
underwent ECG monitoring for 12 hours to calculate individualized heart rate-corrected QT 
intervals (QTcI).
Results—Fifteen subjects completed all study phases. Maximum serum ibutilide concentrations 
in the progesterone and placebo phases were similar (1247±770 vs 1172±709 pg/mL, p=0.43). 
Serum progesterone concentrations were higher during the progesterone phase (16.2±11.0 vs 
1.2±1.0 ng/mL, p<0.0001), while serum estradiol concentrations in the two phases were similar 
(89.3±62.8 vs 71.8±31.7 pg/mL, p=0.36). Pre-ibutilide lead II QTcI was significantly lower in the 
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progesterone phase (412±15 vs 419±14 ms, p=0.04). Maximum ibutilide-associated QTcI (443±17 
vs 458±19 ms, p=0.003), maximum percent increase in QTcI from pretreatment value (7.5±2.4 vs 
9.3±3.4%, p=0.02) and area under the effect (QTcI) curve during the first hour post-ibutilide 
(497±13 vs 510±16 ms-hr, p=0.002) were lower during the progesterone phase. Progesterone-
associated adverse effects included fatigue/malaise and vertigo.
Conclusions—Oral progesterone administration attenuates drug-induced QTcI lengthening.
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QT interval; Torsades de pointes; Electrocardiography; Hormonal therapy; Preventive
Torsades de pointes (TdP) is a polymorphic ventricular tachycardia associated with QT 
interval prolongation (1), which may be induced by more than 100 medications available in 
the Unites States (2). TdP can be catastrophic, often degenerating into ventricular fibrillation 
causing sudden cardiac arrest (3). The risk for TdP increases as the heart rate-corrected QT 
(QTc) interval increases (4,5), particularly exceeding 500 ms (6,7). Consequently, QTc 
interval prolongation is used commonly as a marker of increased risk of TdP.
Female sex is an independent risk factor for TdP in patients with acquired or congenital 
long-QT syndrome (LQTS) (6,8-10). QTc intervals are longer in women than men (11), a 
difference which becomes apparent only after puberty (12), suggesting that sex hormones 
may be responsible. Post-pubertal differences in QTc intervals may be partially due to 
reduction in QTc intervals in males as a result of testosterone and dihydrotestosterone 
production (11). However, other factors may also contribute to the difference in risk of TdP. 
Some studies have reported that hormone replacement therapy with estrogen resulted in QTc 
interval lengthening (13,14).
Progesterone is a testosterone precursor (15) and has a similar androgenic structure (16). 
Higher serum progesterone concentrations are associated with shorter QTc intervals (17) and 
may exert protective effects against lengthening of ventricular repolarization (18). 
Preclinical data suggest that exogenous progesterone administration may protect against 
drug-induced prolongation of ventricular repolarization (19-21), ventricular early 
afterdepolarizations (21) and arrhythmias (22,23). However, the influence of exogenous 
progesterone administration on response to QTc interval-prolonging drugs in humans has not 
been determined.
Few effective strategies have been developed to reduce the risk of drug-induced QTc interval 
prolongation and TdP. We tested the hypothesis that oral administration of progesterone 
attenuates drug-induced QT interval lengthening in young healthy women.
Methods
Study Subjects
Healthy, premenopausal female volunteers age 21-40 years were enrolled. Exclusion criteria 
included: serum potassium <4.0 mEq/L; serum magnesium <1.8 mg/dL; hemoglobin <9.0 
mg/dL; hematocrit <26%; history of hypertension, coronary artery disease, heart failure, 
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liver or kidney disease; serum creatinine >1.5 mg/dL; use of hormonal contraceptives; 
baseline Bazett's-corrected QT interval > 450 ms; personal or family history of LQTS, 
arrhythmias, or sudden cardiac death; concomitant use of any QT interval-prolonging drugs; 
pregnancy; weight < 45 kg; unwillingness to use non-hormonal forms of birth control during 
the study period. This study was approved by the Institutional Review Board at Indiana 
University (IU) Purdue University Indianapolis. All subjects provided written informed 
consent.
Study Procedures
This was a prospective, randomized, double-blind, placebo-controlled, crossover study 
conducted in the Indiana Clinical Research Center (ICRC). Subject recruitment began in 
April, 2013 and study procedures were completed on the last enrolled subject in February, 
2014. The study consisted of three phases: a pre-randomization phase to determine each 
subject's individual QT interval heart rate-correction, and the randomized, double-blind 
progesterone and placebo phases. Prior to inclusion, all subjects underwent a screening 
physical examination and blood was obtained for determination of serum potassium, 
magnesium, creatinine, transaminases, hemoglobin, and hematocrit. A urine human 
chorionic gonadotropin (HCG) test was performed to rule out pregnancy, and a 12-lead 
electrocardiogram (ECG) was obtained. Each study phase was conducted during the menses 
phase of the menstrual cycle (defined as 24-60 hours after menses onset), when serum 
estradiol and progesterone concentrations are at their lowest, to minimize the effects of 
endogenous sex hormones (18).
During the pre-randomization phase, subjects underwent a 12-hour stay in the ICRC. Each 
subject underwent three 12-lead ECGs (Marquette Mac 5500, GE Healthcare Bio-Sciences, 
Pittsburgh, PA) one minute apart, at 0, 15 & 30 minutes, and 1, 2, 4, 6, 8 & 12 hours. ECGs 
were initiated between 7:00 am and 9:00 am, and were completed between 7:00 pm and 9:00 
pm. QT and RR intervals were used to determine each subject's individual heart rate-
corrected QT interval (QTcI) using the parabolic model β•RRα (24), where RR is the 
interval between adjacent QRS complexes, β is the regression coefficient and α is the slope.
The study design is presented in Figure 1. Following the pre-randomization phase, subjects 
were randomized in double-blind fashion to receive oral progesterone 400 mg (2 × 200 mg 
capsules, Teva Pharmaceuticals, North Wales, PA) or matching placebo orally once daily at 
bedtime for 7 days. Matching placebo was prepared by the IU Health Investigational Drug 
Service (IDS). Randomization was performed by the IDS using a computerized random 
number generator and recorded on the IDS randomization log. Participants were assigned to 
progesterone or placebo in each phase by IDS personnel. Progesterone or matching placebo 
were delivered to the ICRC by IDS personnel; investigators, study subjects, and ICRC 
personnel were blinded to treatment assignments during data collection and analysis. The 
minimum desired washout period was 28 days; after 28 days, we initiated dosing 7 days 
prior to the next menstrual cycle, resulting in a total washout period of 49 days.
On the morning after the last dose of oral progesterone or placebo, subjects presented to the 
ICRC for an approximately 13-hour stay. Each subject underwent another urine HCG test to 
assure absence of pregnancy. Three ECGs, one minute apart, were obtained for baseline 
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measurements. If the urine HCG test was negative and the Bazett's-corrected QT interval 
was < 450 ms, subjects were placed on a continuous ECG monitor (Heal Force model PC 
80B, Heal Force Bio-Meditech, Shanghai, China) and one peripheral indwelling intravenous 
catheter was inserted into each arm. Blood (4.5 mL) for determination of serum estradiol 
and progesterone concentrations was collected in gold-top serum separator tubes 
(Vacutainer, Becton Dickinson, Franklin Lakes, NJ).
Subjects then received a single intravenous dose of ibutilide 0.003 mg/kg diluted in 20 mL 
normal saline and infused over 10 minutes (18). Three 12-lead ECGs were obtained one 
minute apart immediately at the end of infusion and at 5, 10, 15, 20, 30, 45 minutes and 1, 2, 
4, 6, 8 & 12 hours post-infusion. Pre-ibutilide ECGs were initiated between 7:00 am and 
9:00 am, and ibutilide was administered immediately following baseline ECGs. ECGs were 
completed between 7:00 pm and 9:00 pm. These times correspond to the same times of day 
as those during which ECGs were obtained for determination of individualized QT interval 
corrections. Blood (10 mL) for determination of serum ibutilide concentrations was obtained 
from the indwelling catheter in the arm contralateral to that into which ibutilide was infused 
and collected in red-top tubes (Vacutainer, Becton Dickinson, Franklin Lakes, NJ) at the 
same times as ECGs were obtained. Subjects underwent continuous ECG monitoring for 6 
hours post-ibutilide. Subjects were discharged after the 12-hour ECG and blood sample, 
providing that their Bazett's-corrected QTc interval was < 450 ms.
QT Interval Measurements
QT intervals were measured from leads II, V1, and V5 by one investigator (HJ) who was 
blinded to subjects’ assigned groups. QT intervals were measured using the MUSE 
automated system (GE Healthcare Bio-Sciences, Pittsburgh, PA) using electronic calipers. 
QT and RR intervals were averaged over ≥ 5 consecutive beats and the average of three QT 
intervals at each time point for each lead was determined. Only clearly discernible QT 
intervals were measured. Determination of the QTcI for each subject was performed as 
described. QT intervals were also corrected using the Fridericia method (QTF) (25).
Determination of Serum Hormone and Ibutilide Concentrations
Serum estradiol and progesterone concentrations were determined in the IU Health 
Pathology laboratory using chemiluminescence immunoassays (26,27). Serum ibutilide 
concentrations were determined in the IU Clinical Pharmacology Analytical Core 
Laboratory using reverse-phase high-performance liquid chromatography with mass 
spectrometry detection. Additional detail regarding this assay is provided in the online 
Appendix in the text, in Appendix Table 1, and in Appendix Figures 1 and 2.
Study Outcome Measures
Outcome measures compared in the progesterone and placebo phases were: 1) Baseline (pre-
ibutilide) QTcI and QTF intervals, 2) Maximum QTcI and QTF intervals following ibutilide 
administration, 3) Maximum ibutilide-induced % change in QTcI and QTF intervals, and 4) 
Area under the QTcI and QTF interval-time curves from 0-1 hour following ibutilide 
administration.
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Data Analysis
Area under the QTcI and QTF interval-time curves were calculated using the linear 
trapezoidal rule. Maximum serum ibutilide concentration was determined via visual 
inspection of serum concentration data.
Sample Size and Statistical Analysis
A sample size of 16 subjects was determined to be sufficient to detect a difference in 
maximum QTcI of 12 ms (19% reduction), assuming a QTcI prolongation of 63±13 ms 
associated with ibutilide in the placebo group and a power of 0.80 (18). Analyses were 
performed using SAS 9.2 (SAS, Cary, North Carolina). Normality of outcome measures data 
was determined using the Kolmogorov-Smirnov test. Comparisons of the outcome measures 
during progesterone and placebo phases were performed using paired Student's t-tests. 
Differences in adverse event proportions were analyzed using the Fisher's Exact Test. 
Potential treatment-period interactions were tested by comparing the mean within-individual 
differences for the progesterone-placebo sequence versus those in the placebo-progesterone 
sequence for each outcome measure using t-tests for paired samples. All comparisons were 
performed utilizing a two-sided α level of 0.05.
Results
Subjects
Nineteen subjects were enrolled (Figure 2). Four subjects were excluded from the outcome 
measures analysis because they did not complete all treatment phases (n=3) or were 
determined to have been nonadherent to study medications after completion of all study 
phases (n=1). Therefore, n=15 subjects comprise the final sample size for analysis of 
outcome measures. For analysis of adverse effects, n=16 received progesterone and n=17 
received placebo; n=15 received ibutilide during the progesterone phase, n=17 received 
ibutilide during the placebo phase. The subjects’ mean age was 29±5 years. Nine subjects 
were white, 5 were black, and 1 was of Middle Eastern descent. Mean weight was 83±20 kg, 
and the mean ibutilide dose was 0.24±0.06 mg.
Serum Ibutilide and Hormone Concentrations
There was no significant difference between the progesterone and placebo phases in 
maximum serum ibutilide (1247±770 vs 1172±709 pg/mL, p=0.43) or serum estradiol 
concentration (89.3±62.8 vs 71.8±31.7 pg/mL, p=0.36). Serum progesterone concentrations 
were significantly higher during the progesterone phase (16.2±11.0 vs 1.2±1.0 ng/mL, 
p<0.0001), as was the serum progesterone: estradiol concentration ratio (205±40 vs 18±16, 
p=0.001).
Individualized QT Interval Heart Rate Correction – Heart Rates
There was no significant difference in minimum heart rate between the pre-randomization 
(development of QTcI) phase and on ibutilide administration days in the placebo and 
progesterone phases (60±7 vs 60±9 vs 61±9 bpm, respectively, p=0.58). There was no 
significant difference in maximum heart rate between the pre-randomization phase and 
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ibutilide administration days in the placebo and progesterone phases (78±8 vs 79±9 vs 
80±11 bpm, respectively, p=0.70). There was no significant difference in average heart rate 
between the pre-randomization phase and on ibutilide administration days in the placebo and 
progesterone phases (68±7 vs 68±8 vs 70±9 bpm, respectively, p=0.51). Heart rates in the 
three study phases are presented in Appendix Figure 3.
Baseline (Pre-Ibutilide) QTcI and QTF Intervals
Baseline (pre-ibutilide) QTcI and QTF intervals in ECG lead II were significantly lower 
during the progesterone phase than during the placebo phase (Figure 3), indicating that oral 
progesterone administration affected ventricular repolarization in the absence of a QT-
lengthening drug. Similar results were demonstrated from ECG leads V1 and V5 (Appendix 
Figures 4 and 5).
QTcI and QTF Intervals Following Ibutilide Administration
Lead II QTcI and QTF intervals prior to and during the first hour following ibutilide 
administration in the progesterone and placebo groups are presented in Figure 4. Similar 
results were demonstrated in leads V1 and V5 (Appendix Figures 6 and 7). The maximum 
lead II QTcI and QTF following ibutilide administration during the progesterone and placebo 
phases are presented in Figure 5. Maximum QTcI and QTF intervals were significantly lower 
during the progesterone phase than during the placebo phase. Similar results were 
demonstrated in leads V1 and V5 (Appendix Figures 8 and 9).
Maximum % Change from Baseline in QTcI and QTF Intervals Following Ibutilide 
Administration
Maximum ibutilide-associated % change in lead II QTcI and QTF intervals from baseline 
values is presented in Figure 6. There were significantly smaller ibutilide-associated % 
changes in QTcI and QTF intervals in the progesterone phase compared with the placebo 
phase. Similar results were shown in leads V1 and V5 (Appendix Figures 10 and 11).
Area Under the QTcI and QTF Interval Versus Time (0-1 hour) Following Ibutilide 
Administration
Area under the lead II QTcI interval versus time (0-1.17 hours, 1 hour after completion of 
ibutilide infusion) curve was significantly lower during the progesterone phase compared 
with the placebo phase (497±13 vs 510±16 ms hr, p=0.002). Similarly, area under the lead II 
QTF interval versus time (0-1.17 hours) curve after ibutilide administration was significantly 
lower during the progesterone phase compared with the placebo phase (499±17 vs 506±15 
ms hr, p=0.013). Similar results were demonstrated with leads V1 and V5 (Appendix Table 
2).
Adverse Effects Associated with Progesterone
Progesterone-associated adverse effects were generally mild, including fatigue/general 
malaise [progesterone 6/16 (38%) vs placebo 1/17 (6%), p=0.04], headache [2/16 (13%) vs 
1/17 (6%), p = 0.60], mood changes [2/16 (13%) vs 0, p=0.23], breast tenderness [2/16 
(13%) vs 0, p=0.23], hypotension [1/16 (6%) vs 0, p=0.48], and vertigo 1/16 (6%) vs 0, 
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p=0.48]. The subject who experienced vertigo and hypotension during progesterone therapy 
withdrew from the study as a result.
Adverse Effects Associated with Ibutilide
There were no differences between the progesterone and placebo phases in ibutilide-
associated adverse effects, which included bradycardia [heart rate < 60 bpm; progesterone 
phase 3/15 (20%) vs placebo phase 2/17 (12%), p=0.65] and burning at the infusion site 
[1/15 (7%) vs 1/17 (6%), p>0.99]. In one subject (during the placebo phase), Bazett's-
corrected QT interval transiently prolonged to > 500 ms.
Potential Treatment-Period Interactions
There were no significant treatment-period interactions for any of the study outcome 
measures.
Discussion
This is the first study to investigate the effect of oral progesterone administration on drug-
induced QT interval lengthening in humans. In this initial proof-of-concept study, we found 
that oral progesterone 400 mg administered daily for one week significantly reduced non-
drug associated QTcI and QTF intervals during the menses phase in young healthy women. 
In addition, oral progesterone attenuated the QTcI and QTF interval response to low-dose 
ibutilide. These findings suggest that oral progesterone could be effective for reducing the 
risk of drug-induced QTc interval prolongation in patients requiring therapy with QTc 
interval-prolonging drugs, and provide support for further investigation of the effect of oral 
progesterone in targeted populations requiring QTc interval-prolonging drug therapy.
Previous studies have suggested that progesterone may be protective against lengthening of 
ventricular repolarization and/or drug-induced arrhythmias. In studies in which hormone 
replacement therapy with estrogen alone prolonged QTc interval, regimens that included 
progesterone did not (13,14,28,29). In women with congenital LQTS, the risk of TdP is low 
during pregnancy, but increases immediately post-partum, when serum progesterone 
concentrations abruptly decline (30). The QTc interval is significantly shorter during the 
luteal phase of the menstrual cycle, when serum progesterone concentrations are highest, 
compared with the follicular phase (17). In healthy volunteers, drug-induced QTc interval 
lengthening is greatest during the menses and ovulation phases and least during the luteal 
phase. There was a significant inverse correlation between serum progesterone 
concentrations and degree of ibutilide-associated QT interval lengthening (18). Progesterone 
shortens ventricular action potential duration in guinea pig ventricular myocytes, effects that 
were reversed by mifepristone, a progesterone receptor inhibitor (20). Progesterone and 
dihydrotestosterone protected against sudden cardiac death in a transgenic rabbit model of 
LQTS type 2, whereas estradiol promoted sudden cardiac death (23).
Potential mechanisms by which progesterone exerts protective effects against lengthening of 
ventricular repolarization and ventricular arrhythmias have been investigated. Nakamura et 
al (20) reported that progesterone enhances the slow component of the delayed rectifier 
current (IKs) and inhibits L-type Ca2+ currents (ICa,L) under cyclic adenosine 
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monophosphate-stimulated conditions in isolated guinea pig myocytes. These effects were 
found to be mediated by nitric oxide release through nongenomic activation of endothelial 
nitric oxide synthase (21). Odening et al (23) found that progesterone decreases the density 
of ICa,L in rabbit cardiomyocytes and increases expression of sarcoplasmic reticulum 
calcium ATPase2a, which may contribute to increasing sarcoplasmic reticular Ca2+ uptake, 
thus shortening Ca2+ transient duration (23). Whether the effects of oral progesterone on 
attenuation of drug-induced QTc interval lengthening are maintained during longer-term 
progesterone therapy or whether there is compensatory lengthening of the QTc interval after 
longer-term progesterone exposure requires additional study.
We selected a progesterone dose of 400 mg daily as this dose is used commonly for 
management of polycystic ovary syndrome (31) and for prevention of preterm birth (32). 
Oral progesterone 400 mg once daily led to a significant reduction in baseline, non-drug-
associated QTcI and QTF intervals. This was an important contributor to the overall effect of 
progesterone-associated reduction in maximum ibutilide-associated QTcI and QTF intervals 
and areas under the QTcI interval and QTF interval versus time curves during the first hour 
following ibutilide administration. However, the effects of progesterone were not solely 
attributable to a reduction in baseline QT intervals. Oral progesterone also exerted a 
protective effect against ibutilide-associated QTcI and QTF interval lengthening, as 
manifested by a reduction in % change in maximum ibutilide-associated QTcI and QTF 
interval from pretreatment values.
Progesterone 400 mg once daily was associated with adverse effects, most of which were 
mild. Additional study is necessary to determine whether a lower dose of oral progesterone 
resulting in proportionately lower serum concentrations is effective for attenuation of drug-
induced QTc interval lengthening. The long-term incidence of adverse effects associated 
with oral progesterone 400 mg daily has not been well-studied. The incidence of adverse 
effects associated with oral progesterone 300 mg daily for 12 weeks was not significantly 
different than that associated with placebo (33). Oral progesterone 400 mg daily 
administered for 18 weeks was associated with no reported adverse effects in pregnant 
women (34). The incidence of adverse effects associated with longer-term administration of 
oral progesterone 400 mg daily requires further study.
Ibutilide prolongs the QT interval in a dose-dependent fashion via inhibition of the rapid 
component of the delayed rectifier potassium current (35), as well through activation of a 
slow inward sodium current (36). Ibutilide was an appropriate probe drug for this 
investigation since serum concentrations peak and decline rapidly after intravenous 
administration (18). We administered a mean dose of 0.24±0.06 mg, 24% of the lowest 
therapeutic dose (1 mg) and 12% of the highest total therapeutic dose (2 mg). This 
subtherapeutic dose was selected based on previous investigations in which ibutilide 0.003 
mg/kg provoked a modest, but not excessive, lengthening of the QTc interval in healthy 
volunteers (18). In our subjects, QTcI and QTF intervals generally returned to baseline 
values within 60-90 minutes of ibutilide administration. There was no significant difference 
in maximum serum ibutilide concentration between the progesterone and placebo phases; 
therefore, differences in QTcI and QTF intervals in the two phases were not attributable to 
differences in serum ibutilide concentration.
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Limitations of this study include the fact that it was conducted in young healthy women 
during the menses phase, when endogenous serum progesterone and estradiol concentrations 
are lowest. It remains unknown whether the effects of oral progesterone would be similar if 
administered during different phases of the menstrual cycle, or to postmenopausal women. 
The range of heart rates in our healthy subjects was relatively narrow during the phase when 
the heart rate-correction factors for the individualized QT interval corrections were 
determined. However, there were no differences in heart rates during the pre-randomization 
phase versus those in the placebo or progesterone phases; therefore, the individualized heart 
rate corrections were derived using a similar range of heart rates during each phase of the 
study. In addition, we also report our results using the Fridericia heart rate correction for QT 
interval, and the QTF results mirror those of our QTcI analysis. The period of progesterone 
administration was relatively short (7 days); the effect of longer periods of progesterone 
administration on naturally occurring QTc interval and drug-induced QTc interval 
lengthening, as well as the safety of long-term oral progesterone, require further study.
Conclusions
Oral progesterone 400 mg daily reduces baseline QTcI intervals and attenuates drug-induced 
QTcI interval lengthening. These findings provide support for additional studies 
investigating the efficacy, safety and clinical feasibility of oral progesterone administration 
for reducing the risk of drug-induced QTc interval prolongation and TdP in patients with risk 
factors who require therapy with QT interval-prolonging drugs.
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HCG Human chorionic gonadotropin
ICRC Indiana Clinical Research Center
IDS Investigational Drug Service
LQTS Long QT syndrome
QTc interval Bazett's-corrected QT interval
QTcI Individualized heart rate-corrected QT interval
QTF Fridericia-corrected QT interval
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IU Indiana University
References
1. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the 
mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 
2007; 153:891–9. [PubMed: 17540188] 
2. Tisdale, JE. Ventricular arrhythmias.. In: Tisdale, JE., Miller, DA., editors. Drug-Induced Diseases. 
Prevention, Detection and Management. 2nd ed.. American Society of Health-System Pharmacists; 
Bethesda, MD: 2010. p. 485-515.
3. Drew BJ, Ackerman MJ, Funk M, et al. on behalf of the American Heart Association Acute Cardiac 
Care Committee of the Council on Clinical Cardiology, the Council on Cardiovascular Nursing, and 
the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital 
settings: a scientific statement from the American Heart Association and the American College of 
Cardiology Foundation. J Am Coll Cardiol. 2010; 55:934–47. [PubMed: 20185054] 
4. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome. Prospective longitudinal study 
of 328 families. Circulation. 1991; 84:1136–44. [PubMed: 1884444] 
5. Zareba W, Moss AJ, Schwartz PJ, et al. Influence of genotype on the clinical course of the long-QT 
syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998; 
339:960–5. [PubMed: 9753711] 
6. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. 
JAMA. 1993; 269:1532–6. [PubMed: 8445816] 
7. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. Inhospital 
cardiac arrest is associated with use of nonantiarrhythmic QTc-prolonging drugs. Br J Clin 
Pharmacol. 2007; 63:216–23. [PubMed: 16869820] 
8. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor 
for torsades de pointes associated with cardiovascular drugs. JAMA. 1993; 270:2590–7. [PubMed: 
8230644] 
9. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de 
pointes with d.l-sotalol. Circulation. 1996; 94:2535–41. [PubMed: 8921798] 
10. Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in 
patients with congenital long-QT syndrome: findings from the International LQTS Registry. 
Circulation. 1998; 97:2237–44. [PubMed: 9631873] 
11. Pham TV, Rosen MR. Sex, hormones, and repolarization. Cardiovasc Res. 2002; 53:740–51. 
[PubMed: 11861044] 
12. Rautaharju PM, Zhou SH, Wong S, et al. Sex differences in the evolution of the 
electrocardiographic QT interval with age. Can J Cardiol. 1992; 8:690–5. [PubMed: 1422988] 
Tisdale et al. Page 10
JACC Clin Electrophysiol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
13. Carnethon MR, Anthony MS, Cascio WE, et al. A prospective evaluation of the risk of QT 
prolongation with hormone replacement therapy: the atherosclerosis risk in communities study. 
Ann Epidemiol. 2003; 13:530–6. [PubMed: 12932629] 
14. Gökçe M, Karahan B, Yilmaz R, Örem C, Erdöl C, Özdemir S. Long term effects of hormone 
replacement therapy on heart rate variability, QT interval, QT dispersion and frequencies of 
arrhythmia. Int J Cardiol. 2005; 99:373–9. [PubMed: 15771916] 
15. Ye L, Su ZJ, Ge RS. Inhibitors of testosterone biosynthetic and metabolic activation enzymes. 
Molecules. 2011; 16:9983–10001. [PubMed: 22138857] 
16. Guyton, AC., Hall, JE. Textbook of Medical Physiology. 11th ed.. Elsevier, Inc; Philadelphia: 
2006. 
17. Nakagawa M, Ooie T, Takahashi N, et al. Influence of menstrual cycle on QT interval dynamics. 
Pacing Clin Electrophysiol. 2006; 29:607–13. [PubMed: 16784426] 
18. Rodriguez I, Kilborn MJ, Liu X-K, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in 
women during the menstrual cycle. JAMA. 2001; 285:1322–6. [PubMed: 11255387] 
19. Tisdale JE, Overholser BR, Wroblewski HA, Sowinski KM. The influence of progesterone alone 
and in combination with estradiol on ventricular action potential duration and triangulation in 
response to potassium channel inhibition. J Cardiovasc Electrophysiol. 2011; 22:325–31. 
[PubMed: 20731743] 
20. Nakamura H, Kurokawa J, Bai CX, et al. Progesterone regulates cardiac repolarization through a 
nongenomic pathway: an in vitro patch-clamp and computational modeling study. Circulation. 
2007; 116:2913–22. [PubMed: 18056530] 
21. Cheng J, Zhang J, Ma X, Su D. Frequency-dependent acceleration of cardiac repolarization by 
progesterone underlying its cardiac protection against drug-induced proarrhythmic effects in 
female rabbits. Eur J Pharmacol. 2012; 689:172–8. [PubMed: 22705061] 
22. Cheng J, Su D, Ma X, Li H. Concurrent supplement of estradiol and progesterone reduces the 
cardiac sensitivity to D,L-sotalol-induced arrhythmias in ovariectomized rabbits. J Cardiovasc 
Pharmacol Ther. 2012; 17:208–14. [PubMed: 21875897] 
23. Odening KE, Choi B-R, Liu GX, et al. Estradiol promotes sudden cardiac death in transgenic long 
QT type 2 rabbits while progesterone is protective. Heart Rhythm. 2012; 9:823–32. [PubMed: 
22245795] 
24. Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals 
is highly individual among healthy subjects: implications for heart rate correction of the QT 
interval. Heart. 2002; 87:220–8. [PubMed: 11847158] 
25. Fridericia LS. Die systolendauer im elektrokardiogramm bei normalen menchen und bei 
herzkranken. Acta Medica Scandinavica. 1920; 53:469–86.
26. Bryant C, Moore J, Curry TE Jr. Determination of serum estradiol levels by radiometric and 
chemiluminescent techniques. Methods Mol Biol. 2009; 590:21–32. [PubMed: 19763495] 
27. Ren S, Wang X, Lin Z, et al. Development of a high-throughput, indirect antibody immobilization 
format chemiluminescence immunoassay (CLEIA) for the determination of progesterone in human 
serum. Luminescence. 2008; 23:175–81. [PubMed: 18452138] 
28. Haseroth K, Seyffart K, Wehling M, Christ M. Effects of progestin-estrogen replacement therapy 
on QT-dispersion in postmenopausal women. Int J Cardiol. 2000; 75:161–5. [PubMed: 11077128] 
29. Kadish AH, Greenland P, Limacher MC, Frishman WH, Daugherty SA, Schwartz JB. Estrogen and 
progestin use and the QT interval in postmenopausal women. Ann Noninvas Electrocardiol. 2004; 
9:366–74.
30. Seth R, Moss AJ, McNitt S, et al. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007; 
49:1092–8. [PubMed: 17349890] 
31. Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med. 
2014; 127:912–9. [PubMed: 24859638] 
32. Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone 
for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane 
Database Syst Rev. 2013; 7:CD004947.
Tisdale et al. Page 11
JACC Clin Electrophysiol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
33. Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms – a placebo-
controlled randomized trial in healthy postmenopausal women. Menopause. 2012; 19:886–93. 
[PubMed: 22453200] 
34. Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD. A randomized trial of 
micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol. 2011; 
28:377–81. [PubMed: 21380990] 
35. Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent 
blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, 
time-, voltage-, and use-dependent effects. Circulation. 1995; 91:1799–1806. [PubMed: 7882490] 
36. Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow 
inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992; 262:99–108. 
[PubMed: 1320693] 
Tisdale et al. Page 12
JACC Clin Electrophysiol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Perspectives
Competency in Medical Knowledge: Torsades de pointes is a potentially life-
threatening polymorphic ventricular tachycardia associated with QT interval 
prolongation, which may be induced by more than 70 medications available in the Unites 
States. Torsades de pointes can be a catastrophic occurrence, as it may degenerate into 
ventricular fibrillation and cause sudden cardiac arrest. Methods for reducing the risk of 
drug-induced QT interval prolongation may result in improved medication safety. 
However, few effective strategies have been developed to reduce the risk of drug-induced 
QTc interval prolongation and torsades de pointes.
Translational Outlook 1: Administration of oral progesterone at a dose of 400 mg daily 
reduces baseline QTcI intervals and attenuates drug-induced QTcI interval lengthening 
during the menses phase of the menstrual cycle in young healthy female subjects.
Translational Outlook 2: These data provide support for additional studies investigating 
the efficacy, safety and clinical feasibility of oral progesterone administration for 
reducing the risk of drug-induced QTc interval prolongation and TdP in patients with risk 
factors who require therapy with QT interval-prolonging drugs.
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Figure 1. 
Study Design
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Figure 2. 
Recruitment and Enrollment for Randomized, Crossover Placebo-Controlled Study of 
Influence of Oral Progesterone on Drug-Induced QTc Interval Lengthening
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Figure 3. 
Influence of Oral Progesterone Administration on Baseline (Pre-Ibutilide) QTcI and QTF 
Intervals (from ECG lead II)
ECG = Electrocardiogram
QTcI = Individually-corrected QT intervals
QTF = Fridericia-corrected QT intervals
Data are presented as mean ± SD
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Figure 4. 
QTcI (4a) and QTF (4b) Intervals During and Following a 10-Minute Infusion of Ibutilide 
0.003 mg/kg (from ECG lead II) During Progesterone and Placebo Phases
ECG = Electrocardiogram
QTcI = Individually-corrected QT intervals
QTF = Fridericia-corrected QT intervals
Data presented as mean ± SEM
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Figure 5. 
Maximum QTcI (5a) and QTF (5b) Intervals (from ECG lead II) Following Ibutilide 0.003 
mg/kg During Progesterone and Placebo Phases
QTcI = Individually-corrected QT intervals
QTF = Fridericia-corrected QT intervals
Data are presented as mean ± SD
Tisdale et al. Page 18
JACC Clin Electrophysiol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Maximum % Change from Baseline in QTcI (6a) and QTF (6b) Intervals (from ECG lead II) 
Following Ibutilide 0.003 mg/kg During Progesterone and Placebo Phases
QTcI = Individually-corrected QT intervals
QTF = Fridericia-corrected QT intervals
Data are presented as mean ± SD
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